Correlation between the in vivo efficacy of GPIIB/IIIA receptor antagonists and ex vivo platelet inhibition:: Role of calcium.

被引：0

作者：

Huang, J ^{[1
]}

Rebello, SS ^{[1
]}

Faul, JD ^{[1
]}

Lucchesi, BR ^{[1
]}

机构：

[1] Univ Michigan, Sch Med, Ann Arbor, MI 48109 USA

来源：

FASEB JOURNAL | 1998年 / 12卷 / 04期

关键词：

D O I：

暂无

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

1113

引用

页码：A191 / A191

页数：1

共 40 条

[31] ANTAGONISTS OF PLATELET-ACTIVATING-FACTOR (PAF) - CORRELATION BETWEEN RECEPTOR-BINDING AND INHIBITION OF WASHED RABBIT PLATELET ACTIVATION INVITRO
COX, CP
PAULSON, SK
FEDERATION PROCEEDINGS, 1987, 46 (03) : 740 - 740
[32] Correlation between the in vitro and in vivo blood-brain barrier permeabilities of H-2 receptor antagonists
Eddy, EP
Olearchyk, RA
Ryan, FM
Hart, TK
Smith, PL
BIOLOGY AND PHYSIOLOGY OF THE BLOOD-BRAIN BARRIER: TRANSPORT, CELLULAR INTERACTIONS, AND BRAIN PATHOLOGIES, 1996, 46 : 125 - 136
[33] Lack of correlation between different methods assessing ex vivo platelet function in aspirin-treated patients - relevance for the definition of aspirin resistance
Renda, G.
Rocca, B.
Zurro, M.
De Cristofaro, R.
De Caterina, R.
EUROPEAN HEART JOURNAL, 2007, 28 : 127 - 127
[34] Platelet inhibition with the glycoprotein IIb/IIIa receptor antagonist Lamifiban in high risk patient subsets: Studies to determine the correlation between platelet-mediated prothrombotic activity and clinical risk
Becker, RC
Ali, O
Harrington, RA
Ball, SP
Spencer, FA
Gore, JM
CIRCULATION, 1997, 96 (08) : 4196 - 4196
[35] Correlation between antifactor Xa activity, thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure.
Brophy, DF
Martin, E
Gehr, TWB
Carr, ME
PHARMACOTHERAPY, 2003, 23 (10): : 1342 - 1342
[36] EX-VIVO INHIBITION OF PLATELET-AGGREGATION IN PATIENTS WITH SEVERE LIMB ARTERIOPATHY TREATED WITH BAY U3405, A SPECIFIC TX A(2) RECEPTOR ANTAGONIST
BELLUCCI, S
KEDRA, W
GROUSSIN, H
JAILLET, N
MOLHOSABATIER, P
ANDREASSIAN, B
TOBELEM, G
THROMBOSIS AND HAEMOSTASIS, 1994, 72 (05) : 659 - 662
[37] ORAL DOSING WITH THE GP-IIB/IIIA RECEPTOR ANTAGONIST SC-54684A INHIBITS THE FORMATION OF PLATELET-RICH THROMBI ON DAMAGED CANINE AORTA MOUNTED IN AN EX-VIVO PERFUSION CHAMBER
BARON, DA
FEIGEN, L
MEYER, B
CHESEBRO, J
FUSTER, V
BADIMON, L
BADIMON, JJ
THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1332 - 1332
[38] 5-Hydroxytryptamine-2A receptor gene (HTR2A) candidate polymorphism T102C):: Role for human platelet function under pharmacological challenge ex vivo
Özdener, F
Gülbas, Z
Erol, K
Ozdemir, V
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2005, 27 (06): : 395 - 400
[39] POTENT IN-VITRO AND IN-VIVO INHIBITORS OF PLATELET-AGGREGATION BASED UPON THE ARG-GLY-ASP-PHE SEQUENCE OF FIBRINOGEN - A PROPOSAL ON THE NATURE OF THE BINDING INTERACTION BETWEEN THE ARG-GUANIDINE OF RGDX MIMETICS AND THE PLATELET GP IIB-IIIA RECEPTOR
ZABLOCKI, JA
MIYANO, M
GARLAND, RB
PIREH, D
SCHRETZMAN, L
RAO, SN
LINDMARK, RJ
PANZERKNODLE, SG
NICHOLSON, NS
TAITE, BB
SALYERS, AK
KING, LW
CAMPION, JG
FEIGEN, LP
JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (13) : 1811 - 1819
[40] Ex Vivo Conditioning Regimen by Reversible Non-Muscle Myosin-II Inhibition and Aryl Hydrocarbon Receptor Antagonism Increases Platelet Recovery and Maintains Long-Term Hematopoietic Reconstitution after Human Bone Marrow Transplantation
Shin, Jae-Won
Buxboim, Amnon
Discher, Dennis E.
MOLECULAR THERAPY, 2012, 20 : S199 - S199

← 1 2 3 4 →